Alliance Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Alliance Pharma kazanç ve gelirin sırasıyla yıllık 69.7% ve 5.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 86.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 10.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

69.7%

Kazanç büyüme oranı

86.2%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	19.6%
Gelir büyüme oranı	5.2%
Gelecekteki özkaynak getirisi	10.7%
Analist kapsamı	Good
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

Mar 24

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

Sep 30

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

May 28

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Mar 30

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Dec 24

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Nov 19

Kazanç ve Gelir Büyüme Tahminleri

AIM:APH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	210	24	34	43	7
12/31/2025	200	20	29	41	7
12/31/2024	189	16	27	40	7
6/30/2024	183	-34	29	30	N/A
3/31/2024	182	-33	30	31	N/A
12/31/2023	181	-33	31	31	N/A
9/30/2023	175	-31	30	30	N/A
6/30/2023	170	-29	29	29	N/A
3/31/2023	169	-25	25	25	N/A
12/31/2022	167	-21	20	21	N/A
9/30/2022	165	-5	26	27	N/A
6/30/2022	163	12	32	34	N/A
3/31/2022	163	10	33	36	N/A
12/31/2021	163	7	34	39	N/A
9/30/2021	155	13	34	39	N/A
6/30/2021	147	18	34	39	N/A
3/31/2021	138	13	36	40	N/A
12/31/2020	130	8	38	42	N/A
9/30/2020	131	10	33	37	N/A
6/30/2020	131	11	29	32	N/A
3/31/2020	133	18	30	34	N/A
12/31/2019	136	25	32	36	N/A
9/30/2019	133	23	28	32	N/A
6/30/2019	130	21	24	27	N/A
3/31/2019	124	20	21	25	N/A
12/31/2018	118	18	19	22	N/A
9/30/2018	112	21	22	24	N/A
6/30/2018	107	24	24	26	N/A
3/31/2018	104	27	N/A	27	N/A
12/31/2017	102	29	N/A	27	N/A
9/30/2017	101	25	N/A	27	N/A
6/30/2017	100	22	N/A	26	N/A
3/31/2017	99	20	N/A	22	N/A
12/31/2016	97	18	N/A	17	N/A
9/30/2016	85	18	N/A	13	N/A
6/30/2016	72	18	N/A	9	N/A
3/31/2016	60	15	N/A	9	N/A
12/31/2015	48	13	N/A	8	N/A
9/30/2015	47	11	N/A	9	N/A
6/30/2015	45	8	N/A	9	N/A
3/31/2015	44	8	N/A	10	N/A
12/31/2014	44	8	N/A	11	N/A
9/30/2014	44	8	N/A	11	N/A
6/30/2014	44	9	N/A	10	N/A
3/31/2014	45	9	N/A	10	N/A
12/31/2013	45	10	N/A	9	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: APH önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.1% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: APH önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: APH önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: APH şirketinin gelirinin (yıllık 5.2% ) UK pazarından (yıllık 3.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: APH şirketinin gelirinin (yıllık 5.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: APH 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 10.7 %).

Alliance Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Alliance Pharma plc Provides Preliminary Results for the Year Ended 31 December 2023

Price target decreased by 7.9% to UK£0.75

Price target decreased by 8.0% to UK£0.84

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Consensus EPS estimates fall by 13%

Recent updates

First half 2024 earnings released: EPS: UK£0.009 (vs UK£0.009 in 1H 2023)

Alliance Pharma plc to Report First Half, 2024 Results on Sep 30, 2024

Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues

Alliance Pharma plc Announces Jeyan Heper to Leave the Business as Chief Operating Officer, Effective 31 August 2024

Is Alliance Pharma (LON:APH) A Risky Investment?

Alliance Pharma plc, Annual General Meeting, Jul 29, 2024

New minor risk - Financial position

Full year 2023 earnings: EPS misses analyst expectations

Alliance Pharma plc Provides Preliminary Results for the Year Ended 31 December 2023

Alliance Pharma plc to Report Fiscal Year 2023 Results on Jun 19, 2024

New minor risk - Share price stability

Amberen, Brand of Alliance Pharma plc, Announces Launch of Amberen ENERGY MOOD SLEEP Gummies

Alliance Pharma plc Announces CEO Changes

Alliance Pharma plc to Report Fiscal Year 2023 Results on Apr 09, 2024

Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

Alliance Pharma plc Announces Board Changes

Price target decreased by 7.9% to UK£0.75

High number of new directors

Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

Alliance Pharma plc Announces Appointment of Non-Executive Directors

Price target decreased by 8.0% to UK£0.84

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023

Alliance Pharma plc to Report First Half, 2023 Results on Sep 26, 2023

Upcoming dividend of UK£0.012 per share at 3.1% yield

Consensus EPS estimates fall by 13%

We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

Consensus EPS estimates fall by 11%

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased by 9.1% to UK£0.92

Alliance Pharma plc Appoints Martin Sutherland as Non-Executive Director

Price target decreased to UK£0.97

Alliance Pharma plc to Report Fiscal Year 2022 Final Results on Mar 21, 2023

Alliance Pharma plc Announces Executive Changes

Logistics Development Group plc acquired a 2.38% stake in Alliance Pharma plc for £5.9 million.

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 17%

Alliance Pharma plc Announces CEO Changes

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Alliance Pharma plc Announces Revenue Guidance for Second Half of 2022

Upcoming dividend of UK£0.011 per share

Alliance Pharma plc Announces Directorate Changes

Alliance Pharma plc to Report First Half, 2022 Results on Sep 20, 2022

Alliance Pharma plc, Annual General Meeting, May 18, 2022

Alliance Pharma plc, Annual General Meeting, May 18, 2022

Insufficient new directors

Price target increased to UK£1.25

Price target increased to UK£1.20

First half 2021 earnings released: EPS UK£0.015 (vs UK£0.003 loss in 1H 2020)

Upcoming dividend of UK£0.011 per share

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Alliance Pharma plc Provides Earnings Guidance for the Full Year of 2021

Independent Non-Executive Director has left the company

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Full year 2020 earnings released: EPS UK£0.015 (vs UK£0.048 in FY 2019)

Price target lowered to UK£1.11

Alliance Pharma plc, Annual General Meeting, May 19, 2021

Price target raised to UK£1.00

Alliance Pharma plc (AIM:APH) acquired Biogix, Inc. for $110 million.

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

New 90-day high: UK£0.79

New 90-day high: UK£0.77

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

New 90-day high: UK£0.76

Analysts update estimates

First half earnings released

New 90-day high - UK£0.77